Psychotropic medications sales during COVID-19 outbreak in Italy changed according to the pandemic phases and related lockdowns

We have investigated the psychotropic medications sales (i.e. benzodiazepines, mood stabilisers and selective serotonin reuptake inhibitors) during the COVID-19 pandemic in the period from March 2020 to February 2021 compared with the same period in the preceding year. This was a retrospective and o...

Full description

Saved in:
Bibliographic Details
Published in:Public health (London) 2021-12, Vol.201, p.75-77
Main Authors: Farina, B., Massullo, C., De Rossi, E., Carbone, G.A., Serraino, R., Imperatori, C.
Format: Article
Language:English
Subjects:
Benzodiazepines
Communicable Disease Control
Coronaviruses
COVID-19
Disease Outbreaks
Humans
Italy - epidemiology
Mental health
Pandemics
Pharmacies
Psychotropic Drugs
Psychotropic medications
Retrospective Studies
Sales
SARS-CoV-2
Serotonin
Serotonin reuptake inhibitors
Serotonin uptake inhibitors
Short Communication
Urban areas
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have investigated the psychotropic medications sales (i.e. benzodiazepines, mood stabilisers and selective serotonin reuptake inhibitors) during the COVID-19 pandemic in the period from March 2020 to February 2021 compared with the same period in the preceding year. This was a retrospective and observational study. Data were obtained from five pharmacies located in a working-class zone populated by approximately 150,000 people in the urban area of Rome (Italy). A general slight increase in psychotropic medications sales was observed during the whole pandemic period compared with the previous year. Our data showed that (1) the percentage of sales seems to vary according to the pandemic phases and related lockdowns and (2) the sales differ between the classes of medications considered.
ISSN:0033-3506
1476-5616
1476-5616
DOI:10.1016/j.puhe.2021.10.005